---
title: "MICROPORT EP expects a half-year net profit attributable to the parent company of 30 million to 35 million yuan, an increase of 76.34% to 105.73% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/249529029.md"
description: "MICROPORT EP expects the net profit attributable to the parent company for the first half of 2025 to be between 30 million and 35 million yuan, an increase of 76.34% to 105.73% year-on-year. The company focuses on the field of cardiac electrophysiology and actively expands the atrial fibrillation treatment market, relying on multiple technological advantages. Thanks to the successful promotion of new products overseas, the company's overseas market sales performance has been outstanding, driving significant growth in overall sales and net profit"
datetime: "2025-07-22T08:02:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/249529029.md)
  - [en](https://longbridge.com/en/news/249529029.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/249529029.md)
---

# MICROPORT EP expects a half-year net profit attributable to the parent company of 30 million to 35 million yuan, an increase of 76.34% to 105.73% year-on-year

According to the Zhitong Finance APP, MICROPORT EP (688351.SH) announced that the company expects the net profit attributable to the parent company's owners for the first half of 2025 to be between RMB 30 million and RMB 35 million, an increase of RMB 12.9873 million to RMB 17.9873 million compared to the same period last year (statutory disclosure data), representing a year-on-year increase of 76.34% to 105.73%.

The company has always focused on deepening and breaking through in the field of cardiac electrophysiology, with a global strategy as the core driving force. Relying on the product matrix and technological advantages of the four major technological paths: "ice, fire, electricity, and magnetism," the company is fully committed to exploring the high-potential market of atrial fibrillation treatment, continuously leading the upgrade of domestic electrophysiology surgical solutions towards full scenarios and high precision. Thanks to the launch and promotion of a series of products such as the TrueForce® pressure monitoring radiofrequency ablation catheter and the disposable star-shaped magnetic positioning catheter in overseas markets, the company's overseas market sales performance has been outstanding, further consolidating the competitive advantage of the company's products in overseas markets. During the reporting period, the company's main business developed well, with overall sales steadily increasing in the first half of the year, significantly boosting the company's net profit year-on-year

### Related Stocks

- [688351.CN](https://longbridge.com/en/quote/688351.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [PRECIOUS-Gold falls with MidEast war in focus after Trump pauses strike](https://longbridge.com/en/news/286878933.md)
- [PRECIOUS-Gold edges higher from over 1-1/2-month low but higher yields cap gains](https://longbridge.com/en/news/286745980.md)
- [JPMorgan lowers 2026 gold forecast, still sees rally towards $6,000 on renewed demand](https://longbridge.com/en/news/286715908.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)